Conceptual review outlines three core therapeutic objectives in vitiligo, highlighting how targeted endpoints can refine clinical trial design and long-term care.
Vitiligo entails three therapeutic objectives: control of autoimmune activity, restoration of melanocyte function, and interruption of disease memory. Distinguishing these goals can refine clinical management, trial endpoints, and therapeutic development in vitiligo and other immune-mediated skin diseases.
No takes yet. Share an insight, caveat, or question.
Valle et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: